FOXP3 and mature T-cell and NK-cell non-Hodgkin lymphoma: Although the majority of patients with PTCL-NOS have a poor clinical outcome, the rapid and fatal progression seen in the FOXP3+ case differs from the typical clinical course of PTCL-NOS in general.